$2.64
+0.06 (+2.33%)
Open$2.56
Previous Close$2.58
Day High$2.67
Day Low$2.56
52W High$13.99
52W Low$2.41
Volume—
Avg Volume1.81M
Market Cap252.99M
P/E Ratio—
EPS$-0.46
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,030.7% upside
Current
$2.64
$2.64
Target
$29.85
$29.85
$17.55
$29.85 avg
$40.51
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 62.53M | 56.87M | 56.55M |
| Net Income | 10.24M | 9.50M | 10.72M |
| Profit Margin | 16.4% | 16.7% | 19.0% |
| EBITDA | 18.97M | 15.63M | 16.61M |
| Free Cash Flow | 7.70M | 5.60M | 6.46M |
| Rev Growth | +23.0% | -7.3% | -7.0% |
| Debt/Equity | 0.80 | 0.99 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.93 | +0.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $352.99 | +1.72% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.88 | +0.66% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $478.81 | +2.22% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $626.31 | +1.34% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $300.33 | +4.22% | 64.3 | 37.13B |